BridgeBio Pharma (BBIO) Operating Expenses (2018 - 2026)

BridgeBio Pharma's Operating Expenses history runs 9 years deep, the most recent figure standing at $300.5 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 35.96% year-over-year to $300.5 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 33.92% YoY), while the FY2025 annual figure was $1.0 billion, up 25.85% from the prior year.
• Operating Expenses came in at $300.5 million for Q1 2026 at BridgeBio Pharma, up from $293.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $300.5 million in Q1 2026 to a low of $128.0 million in Q1 2023.
• A 5-year average of $196.9 million and a median of $179.2 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses slipped 27.02% in 2023 and soared 64.68% in 2024, its largest moves.
• BridgeBio Pharma's Operating Expenses stood at $131.1 million in 2022, then surged by 36.66% to $179.2 million in 2023, then gained by 29.44% to $231.9 million in 2024, then gained by 26.66% to $293.7 million in 2025, then rose by 2.29% to $300.5 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $300.5 million, $293.7 million, and $265.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison